Digestion, fermentation, and pathogen anti-adhesive properties of the hMO-mimic di-fucosyl-β-cyclodextrin

Verkhnyatskaya, Stella A.; Kong, Chunli; Klostermann, C.E.; Schols, Henk A.; Vos, Paul de; Walvoort, Marthe T. C.

doi:10.1039/d1fo00830g

Cited by 2 publications

(1 citation statement)

References 47 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By mimicking microvillus glycoconjugates, they can interact with bacterial receptors, preventing pathogens from attaching to epithelial cells and inhibiting pathogen colonization. Scientific studies strongly suggest that prebiotics contribute to maintaining a healthy microbiome, thereby enhancing the efficacy and mitigating the side effects of cancer treatments ( 97 , 98 ). As of now, there are no published reports on the potential links between prebiotics and PDAC.…”

Section: Perspectives Of Microbiome-based Therapy In Pdacmentioning

confidence: 99%

Unraveling the gut microbiome’s contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives

Tabrizi,

Pourteymour Fard Tabrizi,

Mahmoud Khaled

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The gut microbiome plays a significant role in the pathogenesis of pancreatic ductal adenocarcinoma (PDAC), influencing oncogenesis, immune responses, and treatment outcomes. Studies have identified microbial species like Porphyromonas gingivalis and Fusobacterium nucleatum, that promote PDAC progression through various mechanisms. Additionally, the gut microbiome affects immune cell activation and response to immunotherapy, including immune checkpoint inhibitors and CAR-T therapy. Specific microbes and their metabolites play a significant role in the effectiveness of immune checkpoint inhibitors (ICIs). Alterations in the gut microbiome can either enhance or diminish responses to PD-1/PD-L1 and CTLA-4 blockade therapy. Additionally, bacterial metabolites like trimethylamine N-oxide (TMAO) and lipopolysaccharide (LPS) impact antitumor immunity, offering potential targets to augment immunotherapy responses. Modulating the microbiome through fecal microbiota transplantation, probiotics, prebiotics, dietary changes, and antibiotics shows promise in PDAC treatment, although outcomes are highly variable. Dietary modifications, particularly high-fiber diets and specific fat consumption, influence microbiome composition and impact cancer risk. Combining microbiome-based therapies with existing treatments holds potential for improving PDAC therapy outcomes, but further research is needed to optimize their effectiveness.

show abstract

Section: Perspectives Of Microbiome-based Therapy In Pdacmentioning

confidence: 99%

Unraveling the gut microbiome’s contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives

Tabrizi,

Pourteymour Fard Tabrizi,

Mahmoud Khaled

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Characterization and stabilization of the α-L-fucosidase set from Lacticaseibacillus rhamnosus INIA P603

Curiel

Peirotén

Langa

et al. 2022

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Digestion, fermentation, and pathogen anti-adhesive properties of the hMO-mimic di-fucosyl-β-cyclodextrin

Abstract: Human milk is widely acknowledged as the best food for infants, and that is not just because of nutritional features. Human milk also contains a plethora of bioactive molecules, including...

Cited by 2 publications

References 47 publications

Unraveling the gut microbiome’s contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives

Unraveling the gut microbiome’s contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives

Characterization and stabilization of the α-L-fucosidase set from Lacticaseibacillus rhamnosus INIA P603

Contact Info

Product

Resources

About